Evidence map›Paper›PMID 24736184›Full record

ArticleNeuroImage2014

Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [¹¹C]MePPEP.

Daniela A Riaño Barros, Colm J McGinnity, Lula Rosso, Rolf A Heckemann, Oliver D Howes, David J Brooks, John S Duncan, Federico E Turkheimer, Matthias J Koepp, Alexander Hammers

Open access · hybridAbstract read
In one paragraph

Article in NeuroImage, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  5. Article
  6. Article
  7. Αlpha 5 subunit-containing GABABrain communications · 2021
    Article
  8. Methylphenidate's effects on thalamic metabolism and functional connectivity in cannabis abusers and healthy controls.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
  9. Article
  10. Article
  11. Advances of Molecular Imaging in Epilepsy.Current neurology and neuroscience reports · 2016
    Review
  12. Review
  13. Improved models for plasma radiometabolite correction and their impact on kinetic quantification in PET studies.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Daniela A Riaño BarrosCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK; MRC Clinical Sciences Centre Hammersmith Hospital, London, UK.
Colm J McGinnityCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK; MRC Clinical Sciences Centre Hammersmith Hospital, London, UK.
Lula RossoCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK.
Rolf A HeckemannCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK; Neurodis Foundation, CERMEP, Imagerie du Vivant, Lyon. France.
Oliver D HowesCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK; MRC Clinical Sciences Centre Hammersmith Hospital, London, UK.
David J BrooksCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK; Institute of Clinical Medicine, Aarhus University, Denmark.
John S DuncanDepartment of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, UK; Epilepsy Society, Chalfont St Peter, UK.
Federico E TurkheimerCentre for Neuroimaging, Institute of Psychiatry, King's College London, London, UK.
Matthias J KoeppDepartment of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, UK; Epilepsy Society, Chalfont St Peter, UK.
Alexander HammersCentre for Neuroscience, Department of Medicine, Imperial College London, London, UK; MRC Clinical Sciences Centre Hammersmith Hospital, London, UK; Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, UK; Epilepsy Society, Chalfont St Peter, UK; Neurodis Foundation, CERMEP, Imagerie du Vivant, Lyon. France. Electronic address: alexander.hammers@fondation-neurodis.org.
Hammersmith Hospital · GBEpilepsy Research UK · GBAarhus University Hospital · DKCentre d'Exploration et de Recherche Médicale par Emission de Positons · FRImperial College London · GBWellcome Centre for Human Neuroimaging · GB

Funding

Department of HealthMedical Research Council G0700995Medical Research Council G108/585Medical Research Council G1100809Medical Research Council G1100810Medical Research Council MC_U120036861Medical Research Council MC_U120097115
6 · The paper itself

Abstract

backgroundEndocannabinoids are involved in normal cognition, and dysfunction in cannabinoid-receptor-mediated neurotransmission has been suggested in a variety of neurological and psychiatric pathologies. The type 1 cannabinoid receptor (CB1) is widely expressed in the human central nervous system. The objective of this study was to quantify the test-retest reproducibility of measures of the PET ligand [(11)C]MePPEP in order to assess the stability of CB1-receptor quantification in humans in vivo.

methodsFifteen healthy subjects (eight females; median age 32 years, range 25 to 65 years) had a 90-minute PET scan on two occasions after injection of a median dose of [(11)C]MePPEP of 364 MBq. Metabolite-corrected arterial plasma input functions were obtained for all scans. Eight ROIs, reflecting different levels of receptor densities/concentrations, were defined automatically: hippocampus, anterior cingulate gyrus, inferior frontal gyrus, caudate nucleus, globus pallidus, nucleus accumbens, thalamus, and pons. We used seven quantification methods: reversible compartmental models with one and two tissue classes, two and four rate constants, and a variable blood volume term (2kbv; 4kbv); model-free (spectral) analyses with and without regularisation, including one with voxel-wise quantification; the simplified reference tissue model (SRTM) with pons as a pseudo-reference region; and modified standard uptake values (mSUVs) calculated for the period of ~30-60 min after injection. Percentage test-retest change and between-subject variability were both assessed, and test-retest reliability was quantified by the intraclass correlation coefficient (ICC). The ratio of binding estimates pallidum:pons served as an indicator of a method's ability to reflect binding heterogeneity.

resultsNeither the SRTM nor the 4kbv model produced reliable measures, with ICCs around zero. Very good (>0.75) or excellent (>0.80) ICCs were obtained with the other methods. The most reliable were spectral analysis parametric maps (average across regions±standard deviation 0.83±0.03), rank shaping regularised spectral analysis (0.82±0.05), and the 2kbv model (0.82±0.09), but mSUVs were also reliable for most regions (0.79±0.13). Mean test-retest changes among the five well-performing methods ranged from 12±10% for mSUVs to 16% for 2kbv. Intersubject variability was high, with mean between-subject coefficients of variation ranging from 32±13% for mSUVs to 45% for 2kbv. The highest pallidum:pons ratios of binding estimates were achieved by mSUV (4.2), spectral analysis-derived parametric maps (3.6), and 2kbv (3.6).

conclusionQuantification of CB1 receptor availability using [(11)C]MePPEP shows good to excellent reproducibility with several kinetic models and model-free analyses, whether applied on a region-of-interest or voxelwise basis. Simple mSUV measures were also reliable for most regions, but do not allow fully quantitative interpretation. [(11)C]MePPEP PET is well placed as a tool to investigate CB1-receptor mediated neurotransmission in health and disease.

Indexed as

PyrrolidinonesRadiopharmaceuticalsAdultAgedAlgorithmsBlood VolumeBrainFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyReceptor, Cannabinoid, CB1Reproducibility of Results5-(3-methoxyphenyl)-3-(1-phenylethylamino)-1-(4-trifluoromethylphenyl)pyrrolidin-2-onePyrrolidinonesRadiopharmaceuticalsReceptor, Cannabinoid, CB1CB(1)Intra-class correlation coefficientPositron Emission TomographyReliability

Identifiers

PMID24736184
PMCPMC4283194
OpenAlexW2029755490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.